Compare PLUS & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLUS | BEAM |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | 1996 | 2020 |
| Metric | PLUS | BEAM |
|---|---|---|
| Price | $86.11 | $28.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $48.09 |
| AVG Volume (30 Days) | 180.1K | ★ 1.4M |
| Earning Date | 02-04-2026 | 02-24-2026 |
| Dividend Yield | ★ 1.14% | N/A |
| EPS Growth | ★ 14.25 | N/A |
| EPS | ★ 4.60 | N/A |
| Revenue | ★ $2,285,906,000.00 | $55,701,000.00 |
| Revenue This Year | $14.37 | N/A |
| Revenue Next Year | $3.17 | $26.52 |
| P/E Ratio | $17.95 | ★ N/A |
| Revenue Growth | ★ 9.24 | N/A |
| 52 Week Low | $53.83 | $13.53 |
| 52 Week High | $93.98 | $35.25 |
| Indicator | PLUS | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 42.38 | 63.38 |
| Support Level | $87.62 | $26.25 |
| Resistance Level | $90.10 | $30.50 |
| Average True Range (ATR) | 2.28 | 1.49 |
| MACD | -0.69 | -0.00 |
| Stochastic Oscillator | 16.27 | 68.91 |
ePlus Inc is a provider of technology solutions across the IT spectrum, spanning security, cloud, data center, networking, collaboration, AI, service provider, and critical infrastructure, and emerging solutions, to domestic and foreign organizations across all industry segments. Its solutions leverage a broad range of professional, consultative, and managed services across the technology spectrum. The company possesses top-level engineering certifications with a broad range of IT technologies that enable the company to offer multi-vendor IT solutions that are optimized for each of its customers' specific requirements. It also offers a wide portfolio of technology and other capital asset financing solutions to customers across commercial and government enterprises, designing programs.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.